WILMINGTON, Mass.—Charles River Laboratories International, Inc.
entered into a definitive agreement to acquire Celsis International Ltd.
for $212 million in cash,
subject to customary closing adjustments. Celsis is a leading provider of rapid bacterial detection systems for quality-control testing in the
biopharmaceutical and consumer products industries. Celsis’s systems are principally used for product-release testing to help ensure the safe
manufacture of drugs and consumer products. The acquisition complements Charles River Endotoxin and Microbial Detection’s (EMD) position as a leading
provider of rapid endotoxin testing and bacterial identification for biopharmaceutical manufacturing, and creates the most comprehensive solution for rapid
quality-control testing of biopharmaceutical and consumer products.
The addition of Celsis, with its Advance II™, Accel™, and Innovate™ systems for non-sterile applications, will complement EMD’s
recently introduced PTS-Micro™, a rapid bacterial (bioburden) detection system for sterile biopharmaceutical applications. The comprehensive EMD and
Celsis portfolio is expected to drive increased adoption of EMD’s quality-control testing solutions across both sterile and non-sterile applications,
as clients seek a single provider for their rapid product-release testing needs.
James C. Foster, chairman, president, and CEO of Charles River Laboratories, commented, “The acquisition of Celsis combines leading providers of
endotoxin and bacterial testing and bacterial identification to establish EMD as a comprehensive provider of rapid quality-control testing solutions across
multiple industries. The acquisition nearly doubles the market opportunity for EMD testing products and services, offering access to the consumer products
market in addition to our core biopharmaceutical market. Celsis’s robust financial profile enhances the EMD business, which is our highest-growth and
one of our highest-margin businesses. We expect Celsis to be immediately accretive to non-GAAP earnings per share in 2015, with a more significant
contribution in 2016 and beyond.”
The revenue growth rate for
Celsis is expected to be in the low-double digits for the foreseeable future, with a non-GAAP operating margin higher than the Manufacturing Support segment.
The purchase price implies a multiple of approximately 14x adjusted EBITDA for the last twelve months through March 31, 2015.
The transaction is expected to close in the third quarter of 2015, subject to customary closing
conditions. Based on the anticipated timing of the close, the acquisition is expected to represent approximately 1 percent of Charles River’s 2015
consolidated revenue, and approximately 2.5 percent of 2016 consolidated revenue. It is also expected to be accretive to non-GAAP earnings per share by
approximately $0.05 in 2015 and $0.15 to $0.20 in 2016. The company expects to generate modest operational synergies as a result of the acquisition, with
benefits totaling at least $2 million in 2016. Items excluded from non-GAAP earnings per share are expected to include all transaction-related costs, which
primarily include amortization of intangible assets and certain third-party integration costs.
Celsis is a “clean fit” for Charles River Labs, said health care services analyst Eric W. Coldwell, managing director at the
financial firm Robert W. Baird & Co.
in Chicago, in comments reported in the Boston
“This is exactly the kind of deal you'd like to see
Charles River do,” Coldwell said. “It’s a really big opportunity. It adds new channels to Charles River’s business, everything from
bath and beauty to food and diet. They’re on the bleeding edge of where the world’s going.”
Charles River noted that “This press release contains non-GAAP financial measures, such as non-
GAAP earnings per diluted share, which exclude the amortization of intangible assets and other charges related to our acquisitions and expenses associated
with evaluating acquisitions. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. This press release
also refers to our revenue in both a GAAP and non-GAAP (constant currency) basis. There are limitations in using non-GAAP financial measures, as they are not
prepared in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In
particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful
understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management
measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial
impact of our acquisitions (and in certain cases, the evaluation of such acquisitions, whether or not ultimately consummated) is often large relative to our
overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities, such
as business acquisitions, happen infrequently and the underlying costs associated with such activities do not recur on a regular basis. Presenting revenue on
a constant currency basis allows investors to measure our revenue growth exclusive of foreign currency exchange fluctuations more clearly. Non-GAAP results
also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-
GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of
operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with
applicable rules and regulations. A reconciliation of non-GAAP earnings per share for 2015 and 2016 to the most directly comparable GAAP financial measure
has not been included because it is impracticable to determine the allocation of the purchase price and other necessary adjustments at this